MAGE A10-specific T-cells - Adaptimmune

Drug Profile

MAGE A10-specific T-cells - Adaptimmune

Alternative Names: MAGE A-10 TCR; MAGE A10-transduced lymphocytes

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Adaptimmune
  • Developer Adaptimmune; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Bladder cancer; Head and neck cancer; Malignant melanoma; Urogenital cancer
  • Preclinical Hepatocellular carcinoma; Solid tumours

Most Recent Events

  • 18 Oct 2016 Phase-I clinical trials in Malignant melanoma, Head and neck cancer and Urogenital cancer (Inoperable/Unresectable, Metastatic disease) in USA (unspecified route)
  • 01 Oct 2016 Phase-I clinical trials in Bladder cancer in USA (unspecified route) (NCT02989064)
  • 01 Oct 2016 Phase-I clinical trials in Head and neck cancer in USA (unspecified route) (NCT029890640)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top